Insider Selling: InspireMD (NYSE:NSPR) Insider Sells $25,303.65 in Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 9,923 shares of InspireMD stock in a transaction on Friday, January 31st. The stock was sold at an average price of $2.55, for a total transaction of $25,303.65. Following the transaction, the insider directly owned 1,116,806 shares in the company, valued at approximately $2,847,855.30. This represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Stock Down 2.9%

Shares of NYSE NSPR opened at $1.00 on Friday. The company’s fifty day moving average is $1.38 and its 200-day moving average is $1.66. The stock has a market cap of $46.84 million, a price-to-earnings ratio of -1.33 and a beta of 0.82. InspireMD, Inc. has a twelve month low of $0.97 and a twelve month high of $2.93.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Maxim Group assumed coverage on shares of InspireMD in a research report on Monday, February 2nd. They set a “buy” rating and a $6.00 price target on the stock. Piper Sandler reissued an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Loop Capital set a $5.00 price target on shares of InspireMD in a research report on Tuesday, February 24th. Finally, Lake Street Capital set a $4.00 price target on shares of InspireMD in a research report on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $4.50.

Institutional Investors Weigh In On InspireMD

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC acquired a new stake in InspireMD in the 1st quarter valued at $29,000. Virtu Financial LLC acquired a new stake in InspireMD in the 4th quarter valued at $31,000. XTX Topco Ltd acquired a new stake in InspireMD in the 4th quarter valued at $30,000. Orbimed Advisors LLC increased its stake in InspireMD by 46.9% in the 4th quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock valued at $5,577,000 after buying an additional 1,000,000 shares during the last quarter. Finally, Essex Investment Management Co. LLC acquired a new position in shares of InspireMD during the 4th quarter worth about $203,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about InspireMD

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
• Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
• Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.